Stockreport

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics Inc.  (PTHS) 
PDF ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch [Read more]